Literature DB >> 23076683

The effect of treatments for osteoporosis on mortality.

A Grey1, M J Bolland.   

Abstract

The incidence of osteoporotic fractures increases exponentially in later life, in parallel with the progression of frailty and the risk of dying. Several pharmacologic therapies are now available that reduce the risk of fragility fractures. Data from observational studies report that osteoporotic fractures are associated with an increased risk of dying, particularly in the first few years after an event, and that, in osteoporotic populations, bisphosphonate therapy is associated with a reduced risk of death. Data emerging from randomised controlled trials suggest that drugs which significantly reduce fracture risk might also prolong survival in osteoporotic populations. Further research into the nature, magnitude and mechanisms of the effects of osteoporosis treatments on mortality is required, but in the interim, clinicians and their patients should consider the available data in their deliberations about the use of these medications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23076683     DOI: 10.1007/s00198-012-2176-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  26 in total

1.  Hip fracture and increased short-term but not long-term mortality in healthy older women.

Authors:  Erin S LeBlanc; Teresa A Hillier; Kathryn L Pedula; Joanne H Rizzo; Peggy M Cawthon; Howard A Fink; Jane A Cauley; Douglas C Bauer; Dennis M Black; Steven R Cummings; Warren S Browner
Journal:  Arch Intern Med       Date:  2011-09-26

2.  Bisphosphonates may retrieve endothelial function in vascular diseases similar to statins' effects.

Authors:  A Ugur Ural; Ferit Avcu; Kamile Ozturk
Journal:  Eur J Haematol       Date:  2008-03-10       Impact factor: 2.997

3.  Mortality after all major types of osteoporotic fracture in men and women: an observational study.

Authors:  J R Center; T V Nguyen; D Schneider; P N Sambrook; J A Eisman
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

4.  Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study.

Authors:  L Bondo; P Eiken; B Abrahamsen
Journal:  Osteoporos Int       Date:  2012-05-26       Impact factor: 4.507

Review 5.  Epidemiology and outcomes of osteoporotic fractures.

Authors:  Steven R Cummings; L Joseph Melton
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

6.  Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study.

Authors:  P N Sambrook; I D Cameron; J S Chen; L M March; J M Simpson; R G Cumming; M J Seibel
Journal:  Osteoporos Int       Date:  2010-10-20       Impact factor: 4.507

7.  Mortality after osteoporotic fractures.

Authors:  O Johnell; J A Kanis; A Odén; I Sernbo; I Redlund-Johnell; C Petterson; C De Laet; B Jönsson
Journal:  Osteoporos Int       Date:  2003-10-30       Impact factor: 4.507

8.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

9.  The components of excess mortality after hip fracture.

Authors:  J A Kanis; A Oden; O Johnell; C De Laet; B Jonsson; A K Oglesby
Journal:  Bone       Date:  2003-05       Impact factor: 4.398

10.  Potential mediators of the mortality reduction with zoledronic acid after hip fracture.

Authors:  Cathleen S Colón-Emeric; Peter Mesenbrink; Kenneth W Lyles; Carl F Pieper; Steven Boonen; Pierre Delmas; Erik F Eriksen; Jay Magaziner
Journal:  J Bone Miner Res       Date:  2010-01       Impact factor: 6.741

View more
  8 in total

1.  Bone Health ECHO: telementoring to improve osteoporosis care.

Authors:  E Michael Lewiecki; Matthew F Bouchonville; David H Chafey; Arthur Bankhurst; Sanjeev Arora
Journal:  Womens Health (Lond)       Date:  2015-12-23

Review 2.  Osteoporosis and the orthopaedic surgeon: basic concepts for successful co-management of patients' bone health.

Authors:  Ryan P Farmer; Benoit Herbert; Derly O Cuellar; Jiandong Hao; Philip F Stahel; Robin Yasui; David J Hak; Cyril Mauffrey
Journal:  Int Orthop       Date:  2014-03-21       Impact factor: 3.075

3.  Can antiosteoporotic therapy reduce mortality in MRI-proved acute osteoporotic vertebral fractures?

Authors:  Ying-Chou Chen; Fu-Mei Su; Tien-Tsai Cheng; Wei-Che Lin; Chun-Chung Lui
Journal:  J Bone Miner Metab       Date:  2015-06-04       Impact factor: 2.626

Review 4.  Conservative management of osteoporotic vertebral fractures: an update.

Authors:  A Slavici; M Rauschmann; C Fleege
Journal:  Eur J Trauma Emerg Surg       Date:  2016-12-26       Impact factor: 3.693

5.  Risk of long-term infection-related death in clinical osteoporotic vertebral fractures: A hospital-based analysis.

Authors:  Ying-Chou Chen; Wei-Che Lin
Journal:  PLoS One       Date:  2017-08-09       Impact factor: 3.240

6.  Poor 1st-year adherence to anti-osteoporotic therapy increases the risk of mortality in patients with magnetic resonance imaging-proven acute osteoporotic vertebral fractures.

Authors:  Ying-Chou Chen; Wei-Che Lin
Journal:  Patient Prefer Adherence       Date:  2017-04-27       Impact factor: 2.711

7.  Measurement of urinary N-telopeptides and serum C-telopeptides from type I collagen using a lateral flow-based immunoassay.

Authors:  Kyoung Min Lee; Min Ho Lee; Chin Youb Chung; Woo Kyeong Seong; Sang Dae Lee; Moon Seok Park
Journal:  Sensors (Basel)       Date:  2012-12-24       Impact factor: 3.576

8.  Is raloxifene associated with lower risk of mortality in postmenopausal women with vertebral fractures after vertebroplasty?: a hospital-based analysis.

Authors:  Fu-Mei Su; Ying-Chou Chen; Tien-Tsai Cheng; Wei-Che Lin; Chun-Chung Lui
Journal:  BMC Musculoskelet Disord       Date:  2015-08-19       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.